Here's why the AnteoTech (ASX:ADO) share price has withstood today's sell-off

Here's what might be keeping AnteoTech's stock afloat today.

| More on:
A man screws up his face as his nose is swabbed for a COVID test.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a mad Monday on the ASX as the broader index struggled to mitigate a general sell-off, but the AnteoTech Ltd (ASX: ADO) share price has weathered the storm.

At the market close, the company's stock is trading flat with its previous closing price of 19.5 cents.

Let's take a look at what might have buoyed the biotechnology company's stock today.

A challenging day for some healthcare shares

Some earlier points of Monday's session looked like a blood bath, with a sea of red sweeping over the major indexes.

The broader ASX market improved this afternoon before dropping again, with the S&P/ASX 200 Index (ASX: XJO) trading down 0.37% at the close. The All Ordinaries Index (ASX: XJO) slumped 0.34%.

Their weak performance was also reflected in the S&P/ASX 200 Health Care Index (ASX: XHJ), which was down 0.68% at today's close of trade.

The CSL Limited (ASX: CSL) share price was among the leaders of the plunge, sporting a 1.69% drop. Mesoblast Limited (ASX: MSB) and Nanosonics Ltd (ASX: NAN) shares are also in the red. They have fallen 2.98% and 1.9% respectively.

What's keeping the AnteoTech share price afloat?

Luckily for investors, the AnteoTech share price hasn't suffered alongside many of its peers.

As my Foolish colleague Bernd reported earlier today, there were a few healthcare heavyweights recording decent gains on Monday.

The AnteoTech share price might have been held steady by an expectation that the new COVID-19 variant, Omicron, could bolster additional demand for the company's COVID-19 rapid diagnostic tests.

AnteoTech has developed a rapid testing platform that can be used to identify COVID-19. The company has previously signed agreements that will see its rapid diagnostic instruments distributed in Turkey, Cyprus, Greece, and Romania.

Additionally, the testing device was submitted to the Therapeutic Goods Administration in September for approval for use in Australia.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. and Nanosonics Limited. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »